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Abstract
Screening of mutations that cause -thalassaemia in the Bangladeshi population led to the identification of a patient
with a combination of two rare mutations, Hb Monroe and HBB: -92C>G .T h e-thalassaemia major male individual
was transfusion-dependent and had an atypical -globin gene cluster haplotype. Of the two mutations, Hb Monroe
has been characterized in detail. Clinical effects of the other mutation, HBB: -92C>G ,a r eunknown so far.
Bioinformatics analyses were carried out to predict the possible effect of this mutation. These analyses revealed the
presence of a putative binding site for Egr1, a transcription factor, within the HBB:-92 region. Our literature survey
suggestsacloserelationshipbetweendifferentphenotypicmanifestationsof-thalassaemiaandEgr1expression.
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Thalassaemia is one of the major monogenic disor-
ders worldwide (Weatherall, 2001). Approximately 400
mutations have been reported to cause this disease in the
world population. These mutations show notable variabil-
ity in their prevalence and effects in disease prognosis
(Winichagoon et al., 2000; Thein, 2005). Thus, the pres-
ence of rare mutations with debilitating phenotypic mani-
festations imposes a significant challenge to the successful
implementation of prenatal diagnosis-based disease man-
agement strategies.
A preliminary study reported that the number of
thalassaemicbirthsinBangladeshis7483peryear(Khanet
al., 2005). This study also revealed that 7% of the popula-
tion are carriers of this trait. As part of a screening program
for mutations in -thalassaemic individuals, a combination
of two rare mutations, Hb Monroe (HBB: c. 92G > C) and
HBB: -92C > G, was found in the same male subject, who
presents both mutations in homozygous form (Patient 1 of
Ayub et al., 2010). This study aimed to characterize the
physiologicaleffectscausedbythemutationsinthepatient.
Based on haematological findings, the patient was di-
agnosed as having -thalassaemia major, requiring regular
transfusion. Further confirmation of -thalassaemia was
obtained by haemoglobin electrophoresis, using the Sebia
Hydragel Haemoglobin (E) K 20 system. The patient also
presented mild facial bone deformity.
DNA was isolated using the modified DNAzol
method (Chomczynski et al., 1997; Ayub et al., 2010). A
587bpsegmentoftheHBBgenewasamplifiedusingmeth-
ods described elsewhere (Ayub et al., 2010). The selection
was based on mutation data from other populations (Old,
2001;Vrettouetal.,2003).Theregionincludesasectionof
the upstream sequence, 5’ -UTR, exon 1, intron 1 and part
of exon 2, covering most of the part of HBB gene which
contains the most prevalent five mutations in the Southeast
Asian population (Panigrahi and Marwaha, 2007). The
PCR product was purified using QIAGEN QIAquick PCR
Purification Kit. Then the purified product was sequenced
commercially by Macrogen Inc. (Korea). PCR and subse-
quent sequencing step were repeated.
The propositus’s sequence was compared with the
NCBIRefSeqentryfortheHBBgene(NG_000007.3).The
HbVar database was used for the identification of the pres-
ence of mutations reported in other populations (Patrinos et
al., 2004). The transcription factor binding site was pre-
dicted by AliBaba 2.1 (Grabe, 2002), using the
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Short CommunicationTRANSFAC database of transcription factors (Wingender
et al., 1996).
Haplotypes were determined by analysis of the fol-
lowing polymorphic restriction sites in the -globin gene
cluster:(1)HindII5’of;(2)HindIII5’of
G;(3)HindIIIin
the IVSII 5’ of
A ; (4) HincII in the
b; (5) HindII 3’ of
b;
(6) AvaII in the  and (7) HinfI3 ’ (Orkin et al., 1982;
Rahimietal.,2003;Falchietal.,2005).Additionally,poly-
morphism at XmnI in the 5’ of
G site was also checked, ac-
cording to methods described by Rahimi et al. (2003).
This analysis revealed three single-nucleotide differ-
encesintheproband’ssequencecomparedtotheNCBIref-
erence entry. The differences were: (1) HBB: -92C > G, (2)
HBB: c. 9T > C, and (3) HBB: c. 92G > C. Mutation HBB:
c. 92G > C, also known as Hb Monroe, alters the -globin
codon 30 from Arg to Thr and is present within the donor
splice site of exon-intron junction 1 of the HBB gene. It is
likely that the mutation plays a role in pathogenesis by re-
ducing the splicing efficiency (Gonzalez-Redondo et al.,
1989). Mutation HBB: c. 9T > C is a silent mutation. This
polymorphism was also found in Mediterranean popula-
tions (Atweh and Forget, 1986). The rare mutation HBB:
- 9 2 C>Gi slocated upstream of the transcription start site
(TSS). Search for a putative transcription factor site in
TRANSFAC using AliBaba 2.1 showed the putative Egr1
binding site includes the point of mutation (Figure 1).
Haplotype analysis revealed an atypical haplotype in the
homozygous phase (---+-+- ) .T h epresence and absence
of a restriction enzyme site is represented by + and – signs,
Moosa et al. 407
Figure1-PutativeEgr1bindingsitepresentatthemutationsite.TranscriptionfactorbindingsitepredictedbyAliBaba2.1program(Grabe,2002),using
the TRANSFAC (Wingender et al., 1996) database.respectively.ThepropositushadtheXmnIcuttingsiteinthe
5’ region of
G of both chromosomes.
Hb Monroe was first reported in a transfusion-de-
pendent 15-year-old black female from USA (Gonzalez-
Redondo et al., 1988, 1989). Later on, this mutation was
also found in a limited number of individuals from other
populations, such as Indians (Gupta et al., 1991; Varawalla
et al., 1991), Tunisians (Fattoum et al., 1991) and Tajiks
(Fedorov et al., 1993). The second mutation (HBB: -92
C > G) was previously reported only in a Tajik patient who
incidentally had the Hb Monroe mutation too (Fedorov et
al.,1993).Nevertheless,itisunlikelythatthetwoindividu-
als (patient of current study and the Tajik patient) shared
commonancestry.Toourknowledge,noanalysiswasdone
so far on the possible role of this mutation in disease pro-
gression.
HBB:-92C>Gislocated42bpupstreamoftheTSS.
In eukaryotic systems, upstream regions of TSS are associ-
ated with gene regulation. The experimentally determined
transcription factor binding site (TFBS) from the
TRANSFAC database (Wingender et al., 1996) was
searched for within this region, using the Ali Baba 2.1 pro-
gram (Grabe, 2002). This search showed that the mutation
was present within the predicted binding site of Egr1,a
transcription factor gene. This transcription factor belongs
to the EGR family of C2H2-type zinc-finger proteins. The
products of the target genes it activates are required for dif-
ferentiation, mitogenesis and regulation of erythropoesis.
Egr1 is also known as zif268; Krox-24; NGFI-A; 225;
ETR103.ItisassociatedwiththeCREBsignallingpathway
(Wang et al., 2002).
AninterestingroleofEgr1intheresponsetothedrug
hydroxyurea(HU)hasbeenobservedincellcultureexperi-
ments. Treatment with HU can increase the production of
HbF as well as the haemoglobin content, thus ameliorating
-globin-deficient -thalassaemia (Koren et al., 2008). It
was also found that low-level pulsed doses of HU change
the expression level of a wide range of genes, including
Egr1. The HU treatment increased its expression nearly
2-fold in cell culture experiments (Wang et al., 2002). The
relative role of Egr1 in increasing the -chain: -chain ratio
is yet to be determined.
The imbalance in the -chain: -chain ratio and the
instability of the -chain in -thalassaemia result in the in-
crease of serum-free haem (Ciccoli et al., 1999; Koren et
al., 2008). Free haem results in increased generation of re-
active oxygen species (Ciccoli et al., 2003; Amer and
Fibach, 2004), which in turn results in increased Egr1 ex-
pression via MAPK ERK-1/2, Elk-1 and NF-B (Hasan
and Schafer, 2008). Thus, Egr1 also plays a role in the
ROS-mediated pathogenesis of -thalassaemia.
Although the aforementioned studies coupled with
the bioinformatics analyses of the current study suggest a
possible role of Egr1 in certain forms of -thalassaemia,
our literature survey failed to find any experimental
evidence of Egr1 binding at the HBB: -92 position. Experi-
mental studies on Egr1 binding to the HBB: -92 position
may confirm the prediction of our current study. The effect
ofEgr1inhibitionina-thalassaemiamodelorganismmay
also shed further light on the molecular mechanism of the
role played by Egr1 in the ROS-mediated pathogenesis of
individuals affected by this disease.
Haplotype analysis showed that the patient described
here had an atypical haplotype (---+-+- ) .Both chromo-
somes displayed the same form of polymorphism, which
can be explained by the fact that his parents were sec-
ond/third cousins. The patient was positive for the XmnI
site at the 5’ end of
G. Although a positive correlation be-
tween XmnI polymorphism and HbF level has been re-
ported (Bandyopadhyay et al., 2001), no association
between XmnI polymorphism and incidence of the mild
form of -thalassaemia, namely thalassaemia intermedia
was found (Neishabury et al., 2010).
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